EGFR and non-small cell lung carcinoma: Although activating EGFR mutations are only found in 10–15% of LUAD in white populations and in 40–50% of cases in Asian, EGFR-TKIs have doubled the disease-free survival rate in patients with advanced NSCLC and an EGFR mutation (Maemondo et al., 2010; Arbour and Riely, 2019; Westover et al., 2018).